D'ALESSIO, Andrea
 Distribuzione geografica
Continente #
EU - Europa 66
AS - Asia 60
NA - Nord America 33
Totale 159
Nazione #
SG - Singapore 43
IT - Italia 38
US - Stati Uniti d'America 33
HK - Hong Kong 12
IE - Irlanda 12
NL - Olanda 6
IN - India 4
CZ - Repubblica Ceca 3
DE - Germania 3
AT - Austria 2
CH - Svizzera 1
FI - Finlandia 1
KR - Corea 1
Totale 159
Città #
Singapore 27
Dublin 12
Hong Kong 12
Amsterdam 6
Boardman 5
Mezzomerico 4
Santa Clara 4
Turin 4
Pardubice 3
Deiva Marina 2
Florence 2
Milan 2
Munich 2
New Delhi 2
Novara 2
Uzzano 2
Valduggia 2
Vercelli 2
Vienna 2
Helsinki 1
Seoul 1
Trino 1
Zurich 1
Totale 101
Nome #
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 12
. Optimisation of protection in the medical exposure of recurrent adult patients due to computed tomography procedures: development of recurrent exposures reference levels. 11
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 10
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 10
Cumulative radiation exposure from radiological imaging in patients with Hodgkin and diffuse large b-cell lymphoma not submitted to radiotherapy 10
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 9
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 9
Effective and organ doses in patient undergoing interventional neuroradiology procedures: A multicentre study 8
Reply 8
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 8
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma 8
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 8
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 7
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? 7
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 6
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma 6
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma 5
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials 5
Reply 5
PETAL protocol: A phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma 5
Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial 5
Dissecting the Tumor Microenvironment to Predict Immunotherapy Response in Hepatocellular Cancer 5
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma 5
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study 4
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma 4
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study 4
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 2
Totale 186
Categoria #
all - tutte 3.873
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.873


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024125 30 0 10 7 20 0 14 4 0 3 5 32
2024/202561 6 2 46 4 3 0 0 0 0 0 0 0
Totale 186